Philippe Tramoy

Philippe Tramoy serves as a Partner at Seventure Partners, leading the Quadrivium Fund since November 2013, which supports start-ups in Digital technologies and Life sciences linked to multiple prestigious academic institutions. In addition, Philippe holds board member positions at various biotechnology companies, including CryoCapCell, PEP-Therapy, and Aenitis Technologies, focusing on innovative solutions in sample preparation and targeted therapies. Philippe's extensive experience also includes board roles at Scipio Bioscience, myBrain Technologies, Keen Eye Technologies, MilliDrop, DIABNEXT, and horseCom. Philippe Tramoy's academic background includes advanced degrees in Marketing, Finance, Immunology & Molecular Biology, and Biochemistry from esteemed institutions such as HEC Paris, IAE Paris, École normale supérieure de Lyon, and Université de Bourgogne.